Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

100%

7 of 7 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 3

2(25.0%)

Phase 1

2(25.0%)

8Total

Phase 2(4)

Phase 3(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02996305Phase 2Completed

A Study in Adults and Adolescents With Angelman Syndrome (STARS)

Role: lead

NCT03882918Phase 3Terminated

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome

Role: lead

NCT03697161Phase 2Completed

A Study of OV101 in Individuals With Fragile X Syndrome

Role: lead

NCT04106557Phase 3Completed

A Study of OV101 in Individuals With Angelman Syndrome (AS)

Role: lead

NCT03694275Phase 2Completed

A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

Role: collaborator

NCT03650452Phase 2Completed

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Role: collaborator

NCT03166215Phase 1Completed

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

Role: collaborator

NCT03109756Phase 1Completed

Single Dose Pharmacokinetic (PK) Study

Role: lead

All 8 trials loaded